Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Key points
- Eli Lilly (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, with adjusted EPS of $7.48.
- Mounjaro revenue climbed 65% to $10.7 billion, while Zepbound revenue increased approximately 48%–49% to $5.3 billion–$5.4 billion.
- Lilly raised its 2026 revenue outlook to $91 billion–$92 billion and set adjusted EPS guidance at $35–$36 per share.
Eli Lilly and Company (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, beating analyst expectations as strong demand for its weight-loss and diabetes medicines supported growth.
Adjusted earnings per share reached $7.48, while GAAP net income increased to $6.45 billion from $5.58 billion a year earlier.
GAAP diluted EPS rose to $7.22 from $6.21.
Mounjaro revenue increased 65% to $10.7 billion, while Zepbound revenue grew approximately 48%–49% to between $5.3 billion and $5.4 billion.
Foundayo, Lilly's oral GLP-1 medicine, generated $184 million in its first full quarter, below analyst expectations of approximately $234 million.
Lilly raised its full-year 2026 revenue guidance to $91 billion–$92 billion.
Adjusted EPS guidance was set at $35–$36 per share, reflecting improved underlying performance offset by acquired in-process research and development charges from recent business development deals.
Frequently asked questions
More from United States
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
Enerflex Q3 free cash flow rises to $102 million as net earnings climb
WTW Q3 revenue rises 8% to $2.46 billion as AI savings plan advances
Axalta reports higher Q3 sales but lower net income of $95M
Bunge Q3 earnings beat estimates as net income rises to $318 million
